Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457749 | 0.81 | NPSR1 (0.45) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL4840431 | 0.79 | NPSR1 (0.46) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL10047375 | 0.79 | NPSR1 (0.61) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL13449264 | 0.79 | CYP3A4 (0.47) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL9230667 | 0.79 | CYP2D6 (0.47) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5527398 | 0.79 | OPRL1 (0.49) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL4841029 | 0.78 | NPSR1 (0.45) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL4837814 | 0.77 | NPSR1 (0.44) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15797515 | 0.76 | NPSR1 (0.57) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL9359082 | 0.76 | NPSR1 (0.57) | NPSR1GPR55CYP2D6CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1687296-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049602-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| US-5576320-A | 1-heteruarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-11-19 | — | — | US | disclosed |
| US-5565474-A | 1-heteroarylazetidines and -pyrrolidines process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-10-15 | — | — | US | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0406112-B1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-5073646-A | Chemical intermediates, microbiocides | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-12-17 | — | — | US | disclosed |
| EP-0406112-A1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | NPSR1 3802/4885GPR55 4545/4885CYP2D6 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.